{"Clinical Trial ID": "NCT00398567", "Intervention": ["INTERVENTION 1:", "Part 2 - Extended BAT Cohort", "All subjects receiving HKI-272 (neratinib) in combination with trastuzumab (Herceptin) HKI-272: neratinib 240 mg orally daily Herceptin: Herceptin 4 mg/kg IV at a loading dose followed by Herceptin 2 mg/kg weekly thereafter"], "Eligibility": ["Incorporation criteria:", "\u2022 Pathological diagnosis of breast cancer with current stage IIIB, IIIC or IV not curable by available treatment", "Progression after at least one cytotoxic chemotherapy regimen containing herceptin (neoadjuvant, adjuvant or metastatic)", "HER2 positive breast cancer", "At least one measurable target injury", "Adequate progress", "Adequate cardiac, renal and hepatic function", "A proper blood count", "\u2022 Willingness of all subjects who are not surgically sterile or postmenopausal to use acceptable methods of contraception", "- Exclusion criteria:", "More than 3 prior cytotoxic chemotherapys for locally advanced or metastatic disease", "Major surgery, chemotherapy, radiotherapy, research agents, Herceptin or other cancer treatment within 2 weeks of treatment", "Prior treatment with anthracyclines at a cumulative dose of > 400 mg/m^2", "Very large visceral disease", "Metastasis of the active central nervous system", "Pregnant or lactating women", "Important chronic or recent gastrointestinal disorder with diarrhoea as a major symptom", "A prior exposure to HKI-272 or other HER2-targeted agents (except Herceptin and Tykerb)", "A significant heart disease or dysfunction", "Life-threatening history of hypersensitivity to Herceptin", "Inability or unwillingness to swallow HKI-272 capsules", "Any other cancer within 5 years, with the exception of contralateral breast cancer, properly treated cervical carcinoma in situ or properly treated basal or squamous skin carcinoma"], "Results": ["Performance measures:", "16-week progression-free survival rate (PFS)", "16-week progression-free survival rate (PFS) in subjects with advanced breast cancer who receive neratinib at the maximum tolerated dose (LMD) in combination with trastuzumab, an estimated population.", "Duration: from first dose to progression (PD or death) at 16 weeks", "Results 1:", "Title of arm/group: Part 2 - Extended BAT Cohort", "All subjects receiving HKI-272 (neratinib) in combination with trastuzumab (Herceptin) HKI-272: neratinib 240 mg orally daily Herceptin: Herceptin 4 mg/kg IV at a loading dose followed by Herceptin 2 mg/kg weekly thereafter", "Total number of participants analysed: 28", "Type of measurement: Number", "Unit of measure: percentage of population 44.8 (25.9-62.1)"], "Adverse Events": ["Undesirable Events 1:", "Total: 1/4 (25.0%)", "Vertigo 0/4 (0.00 %)", "Abdominal membership 0/4 (0.00 %)", "- Abdominal distension 0/4 (0.00 %)", "Abdominal pain 0/4 (0.00 %)", "Diarrhoea 0/4 (0.00 %)", "- Nausea 0/4 (0.00 %)", "Vomiting 0/4 (0.00 %)", "\u2022 Disease progression 0/4 (0.00 %)", "Influenza 0/4 (0.00 %)", "Nasopharyngitis 0/4 (0.00 %)", "- Lumbar vertebral fracture 0/4 (0.00 %)", "Hyponatraemia 0/4 (0.00 %)", "Ataxia 0/4 (0.00 %)"]}